Recent studies suggest that there is no reliable rapid means for evaluating the carcinogenic potential of chemicals considered to be carcinogens. Carcinogenic bioassays are typically time-consuming and expensive 1.5-or 2-year studies using mice and rats. Alternative animal models using transgenic or gene targeting technologies (Eastin, 1998) or two-stage carcinogenesis models (Tamano, 2010) are also expensive and time-consuming or have limited target organs. Toxicogenomic approaches for prediction of carcinogenic potential in each target organ appear promising. However, they are also expensive and require some integrative methodologies between ABSTRACT -We have previously reported that renal carcinogens examined in rats increase tubular cell proliferation and topoisomerase (Topo) IIα + cells. The present study was aimed at identifying early prediction markers of carcinogens after 28-day treatment in rats. Following gene expression screening by microarrays in renal tubules with renal carcinogens, immunohistochemical analysis and TUNELassay were performed with carcinogens targeting different organs. All renal carcinogens tested (ferric nitrilotriacetic acid, ochratoxin A (OTA), monuron, tris(2-chloroethyl) phosphate, and potassium bromate) increased tubular cells immunoreactive for minichromosome maintenance 3 (Mcm3) or ubiquitin D (Ubd) or those showing apoptosis, compared with untreated controls or non-carcinogenic renal toxicants. Carcinogens targeting the liver (thioacetamide (TAA), fenbendazole, piperonyl butoxide (PBO) and methyleugenol), thyroid (sulfadimethoxine), urinary bladder (phenylethyl isothiocyanate), forestomach (butylated hydroxyanisole), glandular stomach (catechol), and colon (chenodeoxycholic acid and 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine) were examined for induction of Mcm3, Ubd, Topo IIα, Ki-67 and apoptosis using non-carcinogenic toxicants as negative controls. All carcinogens increased Mcm3 + , Ubd + , Topo IIα + , Ki-67 + or TUNEL + cells, except for hepatocarcinogen PBO and both colon carcinogens, which did not increase cell proliferation. Ubd + cells co-expressing Topo IIα was increased without changing phospho-Histone H3-co-expressing cell population as examined with OTA and TAA. Results revealed cooperative responses of Topo IIα, Ubd and apoptosis by carcinogens inducing high proliferation activity, irrespective of target organs, examined here after a 28-day administration. Aberrant expression of Ubd at G 2 phase and increased apoptosis reflecting aberrant cell cycle regulation may be the common feature of these carcinogens.
INTRODUCTION
different laboratories sharing an expression database (Uehara et al., 2011) .
Development of nuclear enlargement is sometimes observed in carcinogenic target cells after repeated administration of carcinogens, irrespective of genotoxic potential, from the early stages of exposure in experimental animals (Allen et al., 2004; Adler et al., 2009 ). This nuclear change is typically observed in the kidney and liver, and often called as karyomegaly when it occurs in renal tubular cells and as cytomegaly in case of liver cells because of accompanying cytoplasmic enlargement. Recent studies have shown that ochratoxin A (OTA), a representative renal carcinogen that can typically induce karyomegaly, induces aberrant expression of cell cyclerelated molecules in the proximal tubular areas of the outer stripe of the outer medulla (OSOM) with karyomegaly (Adler et al., 2009) . This suggests that this aberrant expression may eventually cause carcinogenicity in association with the development of chromosomal instability. We therefore hypothesize that an early event which disrupts cell cycle regulation triggers the carcinogenic response in the molecular mechanism responsible for the development of karyomegaly.
To verify our hypothesis above mentioned, we have previously analyzed the cell cycle-related molecules in a study of 28-day repeated administration of renal carcinogens to induce karyomegaly in rats (Taniai et al., 2012) . The responses suggested an increase in the tubular OSOM cellular population undergoing cell cycle arrest following DNA damage. We also found that renal carcinogens, irrespective of karyomegaly-inducing potential, increased the number of proximal tubular cells positive for Ki-67, a cell proliferation marker, and topoisomerase (Topo) IIα, suggesting proliferation is accompanied by cell cycle aberration ( Supplementary Fig. 1 ). These findings suggested that renal carcinogens, irrespective of karyomegaly-inducing potential, could activate cell proliferation and cell cycle aberration of proximal tubular cells after shortterm repeated administration.
There is a need for a high-precision prediction tool to assess the carcinogenic potential of chemicals. To establish a short-term carcinogenicity prediction system, it is reasonable to focus on common cellular responses in the specific target organs. In the present study, we first focused on the possible relation of the mechanism responsible for induction of karyomegaly to carcinogenesis and applied global gene expression analysis using microarrays to identify genes responding to karyomegalyinducing carcinogens in the renal tubules. Based on gene expression data, we examined cell proliferation activity and apoptosis as well as distribution of cell cycle-related molecules for which immunohistochemical analysis can be applied in proximal tubular cells of rats treated with renal carcinogens. Because of the possible involvement of cell cycle aberration by renal carcinogens irrespective of karyomegaly-inducing potential, we examined responses against renal carcinogens lacking induction of karyomegaly as well as karyomegaly-inducing ones. Expression of these candidate markers was also explored in other target organs, including the liver, thyroid, urinary bladder, forestomach, glandular stomach, and colon, after treatment with organ-specific carcinogens, irrespective of inducing potential of karyomegaly/cytomegaly.
MATERIALS AND METHODS

Chemicals
Iron ( Ochratoxin A (OTA; CAS No. 303-47-9) was extracted from culture of Aspergillus ochraceus (BD-5) and ferric nitrilotriacetic acid (Fe-NTA) was prepared using iron (III) nitrate nonahydrate and NTA disodium salt according to the method described previously (Toyokuni et al., 1994) . The purity of OTA was estimated to be > 95% from the area percentage of the chromatogram (data not shown).
Animal Experiments
Five-week-old male F344/NSlc rats were purchased from Japan SLC, Inc. (Shizuoka, Japan) and acclimatized to a powdered basal diet (Oriental Yeast Co., Ltd., Tokyo, Japan) and tap water ad libitum. They were housed in stainless steel cages in a barrier-maintained animal room on a 12 hr light-dark cycle and conditioned at 23 ± 3°C with a relative humidity of 50 ± 20%.
Animal studies consisted of two experiments. Experiment 1 tested the effects of renal carcinogens on the global gene expression profiles and immunohistochemical cellular responses or apoptosis in the renal tubules. Experiment 2 tested the cellular responses of other carcinogenic targets against renal carcinogen-responding markers. After a one-week acclimatization period, animals were randomized into groups of 10 each and treated with carcinogens or non-carcinogens for 28 days as described (Fig. 1) .
Experiment 1
The design of Experiment 1 targeting the kidney was identical to that previously reported (Taniai et al., 2012) . Fe-NTA, OTA (210 μg/kg body weight, daily by gavage), and MON (3,000 ppm in diet) were selected as karyomegaly-inducing renal carcinogens. The dose or dosing regimen of these compounds has shown to induce karyomegaly in the proximal tubules as well as renal tumors in rats (Li et al., 1987; Nishiyama et al., 1995; NTP, 1988 NTP, , 1989 . PNBA (10,000 ppm in diet) was selected as a karyomegaly-inducing non-carcinogen, and the dose of compound has shown to induce karyomegaly after 13-week administration in rats (NTP, 1994) . TRCP (350 mg/kg body weight, daily by gavage) and KBrO 3 (500 ppm in drinking water) were selected as non-karyomegaly-inducing renal carcinogens, and the dose of these compounds has shown to induce renal carcinogenicity in rats (NTP, 1991; Umemura et al., 2006) . APAP (12,500 ppm in diet) was selected as a non-karyomegaly-inducing renal toxicant, and the dose of APAP has shown to induce renal toxicity after 13-week administration in rats (NTP, 1993) . OTA was dissolved in 0.1 M NaHCO 3 solution and TRCP was dissolved in corn oil. Fe-NTA was intraperitoneally injected into animals at 5 mg/kg body weight as iron for the first 3 days, followed by injections of 10 mg iron/kg body weight for the next 2 days and then 5 days a week according to a previous report (Nishiyama et al., 1995) .
Experiment 2
Animals were treated with carcinogenic dose of carcinogens targeting either of the liver, thyroid, urinary bladder, forestomach, glandular stomach, or colon. TAA (400 ppm in diet), FB (3,600 ppm in diet), PBO (20,000 ppm in diet), or MEG (1,000 mg/kg body weight, daily by gavage) was administered to target the liver. The dose of these compounds has shown to induce liver tumors or promote liver carcinogenesis in rats (Shoda et al., 1999; NTP, 2000; Muguruma et al., 2007; Ichimura et al., 2010) . APAP (12,500 ppm in diet) and ANIT were used as non-hepatocarcinogenic control compounds, and the dose Fig. 1 . Experimental design. Vol. 37 No. 6 of these compounds has shown to induce hepatotoxicity after 13-or 16-week administration in rats (NTP, 1993; Rees et al., 1962) . In the present study, the initial dose of ANIT was set at 1,000 ppm in diet, but the dose was gradually reduced to 800 ppm for 14 days and 600 ppm for 7 days after general health worsened. Other groups received either SDM (1,000 ppm in drinking water) targeting the thyroid, PEITC (1,000 ppm in diet) targeting the urinary bladder, BHA (20,000 ppm in diet) targeting the forestomach, catechol (8,000 ppm in diet) targeting the glandular stomach, or CDCA (1,000 ppm in diet) or PhIP (400 ppm in diet) targeting the colon. The dose of SDM and CDCA has shown to promote carcinogenesis in the thyroid and colon, respectively in rats (Imai et al., 2004; Ghia et al., 1996) . On the other hand, the dose of PEITC, BHA, catechol and PhIP has shown to induce tumors in each target organ (Sugiura et al., 2003; Kaneko et al., 2002; Hagiwara et al., 2001; Ito et al., 1991) . Caprolactam (10,000 ppm in diet) was selected as a non-carcinogenic control compound, showing positivity in some genotoxicity studies (IARC, 1999) . This compound has shown nocarcinogenic effect in any organs with ≥ 7,500 ppm in diet (Fukushima et al., 1991; NTP, 1982) . MEG was suspended in methyl cellulose for administration. Two independent animal studies consisting of groups of SDM, PEITC and CDCA or those of BHA, catechol and PhIP were performed with respective untreated controls and caprolactam-treatment group.
In both Experiments 1 and 2, one day after the 28-day treatment, all animals were killed by exsanguination from the abdominal aorta under deep anesthesia with ether and target organs were removed. In Experiment 1, half of the left and right kidneys were vertically sliced along the length of the center and fixed with methacarn solution for 5 hr, then dehydrated by ice-cold absolute ethanol overnight at 4°C (Shibutani et al., 2000) . The remaining kidney tissues in Experiment 1 and other target organs in Experiment 2 were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer solution (pH7.4; Wako Pure Chemicals Industries, Ltd.). At autopsy, urinary bladder was inflated by transurethral instillation of paraformaldehyde solution, and stomach and colon were instilled with paraformaldehyde solution to facilitate mucosal fixation. The following samples were taken from fixed tissues and prepared for paraffin embedding: bilateral slices of the kidneys; one slice each from the median and left lobes of the liver; bilateral lobes of the thyroid; two longitudinal slices of the urinary bladder; three longitudinal slices of the stomach including forestomach and glandular stomach; and three cross cut pieces each from proximal, medial, and distal portions of the colon. 
Expression microarray analysis
To obtain gene expression profiles showing up-or down-regulation for each karyomegaly-inducing renal carcinogen, kidneys from rats treated with Fe-NTA or OTA were subjected to microarray analysis. Results were compared with kidneys from rats treated with PNBA, a karyomegaly inducing non-carcinogen, and untreated controls (n = 4 animals/group).
Portions of OSOM from methacarn-fixed kidney slices stored in ethanol at 4°C were collected using a biopsy punch (Ф1.5 mm, Kai Industries Co., Ltd., Gifu, Japan) and stored in ethanol at -80°C until extraction. Total RNA of the OSOM was extracted with an RNeasy Mini Kit (QIAGEN, Hilden, Germany), in accordance with the manufacturer's instructions. Using 10 μg of total RNA from one animal from each group, double-stranded cDNA was synthesized with the Invitrogen Superscript Double-Stranded cDNA Synthesis kit (Invitrogen Corporation, Carlsbad, CA, USA), in accordance with the manufacturer's protocol. After labeling with Cy3, 4 μg of each Cy3-labeled cDNA sample was loaded onto the Rattus norvegicus Roche NimbleGen microarray for Gene Expression (Roche NimbleGen: Euk Expr 4x72K Catalog Arr Del, 26,208 targets; Roche Applied Science, Penzberg, Germany). Using a robust multi-array average normalization method (Irizarry et al., 2003) , the commonly up-or down-regulated genes were statistically analyzed between Fe-NTA-or OTA-treatment group in comparison with the untreated control group using Tukey's multiple comparison test with multiple testing corrections applying Benjamini and Hochberg false positive discovery rate calculations, and genes showing statistical significance with a P value < 0.05 were selected. To identify candidate markers for immunohistochemistry, genes that were up-regulated in Fe-NTA-and OTA-treatment groups by ≥ 2-fold compared with untreated controls and by ≥ 1-fold compared with PNBA-treated controls were selected. Gene information was retrieved from the National Center for Biotechnology Information website (http://www.ncbi. nlm.nih.gov).
samples following Fe-NTA or OTA treatment compared with untreated controls (n = 6 animals/group). We additionally examined mRNA expression of Tp53 and apoptosis-related genes, Bax, Bcl2 and Bcl2l1.
Reverse transcription for cDNA synthesis on total RNA samples (2 μg) obtained from OSOM was performed using the Thermoscript RT-PCR System (Invitrogen Corporation) according to the manufacturer's protocol. Quantitative real-time RT-PCR with Power SYBR ® Green PCR Master Mix (Applied Biosystems Inc., Carlsbad, CA, USA) was performed using a Step OnePlus™ Realtime PCR System (Applied Biosystems Inc.). The PCR primers were designed using Primer Express software (Version 3.0; Applied Biosystems, Inc.). The sequences of PCR primers are listed in Table 1 . The amount of target gene expression was normalized to an endogenous reference (Hprt) and relativity to control was obtained using the 2 -ΔΔC T method (Livak and Schmittgen, 2001 ).
Histopathology, immunohistochemistry, and apoptosis assay
Three micrometer sections of paraffin-embedded tissues from the kidneys, liver, thyroid, urinary bladder, stomach, and colon were stained with hematoxylin and eosin for histopathological examination and subjected to immunohistochemistry.
Immunohistochemistry was performed using the Vectastain Elite ABC Kit (Vector Laboratories Inc., Burlingame, CA, USA) with 3, 3'-diaminobenzidine/H 2 O 2 as the chromogen. The following primary antibodies were used: (Taniai et al., 2012) . Ki-67 is a cell proliferation marker expressed during the G 1 to M phase of the cell cycle (Scholzen and Gerdes, 2000) . Topo IIα unlinks DNA catenation from the late S to the G 2 and M phases (Goswami et al., 1996; Bower et al., 2010) . Mcm3 and Ubd were selected because mRNA expression was upregulated in the OSOM following Fe-NTA or OTA treat- Because apoptosis-related genes were up-regulated in the OSOM following treatment with Fe-NTA and OTA in Experiment 1, we examined the induction and frequency of apoptosis at the early stage of carcinogen treatment. Sections of all target organs in both Experiment 1 and 2 were subjected to terminal deoxynucleotidyl transferasemediated dUTP nick-end labeling (TUNEL) assay using the ApopTag ® Peroxidase In Situ Apoptosis Detection Kit (Millipore, Billerica, MA, USA) according to the manufacturer's protocol. Briefly, deparaffinized sections were treated with 20 μg/ml proteinase K for 15 min at room temperature. Endogenous peroxidase activity was blocked with 3.0% hydrogen peroxide. Color development and counter staining were as described above for immunohistochemistry.
Analysis of immunoreactivity
Immunohistochemical analysis in Experiment 1 was performed on either OSOM or whole cortical area and OSOM, indicated as "cortex + OSOM", and the immunostained cells were counted in 8 randomly selected areas avoiding portions of connective tissues and vasculatures per animal (4 areas per kidney) at 400 × magnification.
In Experiment 2, the immunostained cells in the liver were counted in 10 randomly selected areas avoiding portions of connective tissues and vasculatures per animal at 200 × magnification. In the thyroid and urinary bladder, immunostained cells in the follicular area (thyroid) and mucosal area (urinary bladder) were counted in 8 randomly selected areas per animal (4 areas per tissue section) at magnifications of 400 × in the former and 200 × in the latter. In the forestomach, because cells immunoreactive for Ki-67, Mcm3, or Topo IIα were diffusely distributed in the basal cell layer, vertical length of positive cell distribution from the basement membrane was measured in 10 randomly selected areas per animal at 200 × magnification. Ubd + and TUNEL + cells in the forestomach were counted in 10 randomly selected areas in the mucosa per animal at 200 × magnification. In the glandular stomach, immunoreactive cells were counted in 10 randomly selected glands per animal at 200 × magnification. In the colon, immunoreactive cells were counted in 10 randomly selected crypts located close to the lamina muscularis mucosa and exhibiting cross sectional view per animal at 200 × magnification.
Total cells including carcinogenic target cells and other surrounding cells such as stromal cells were measured by counting all nuclei in each selected field in the kidneys in Experiment 1, and in the liver, thyroid, and urinary bladder mucosa in Experiment 2 using WinROOF image analysis and measurement software (version 6.4.2., Mitani Corporation, Fukui, Japan). Percentage of immunoreactive target cells was determined in each field. In the forestomach, mean vertical length of the distribution of Ki-67 + , Mcm3 + , or Topo IIα + cells within the mucosa were estimated from 10 fields and expressed as vertical length (μm). Ubd + or TUNEL + cell counts were expressed as numbers per 1,000 μm of epithelial layer length in each field. In the glandular stomach, mean number of immunoreactive cells of 10 glands/animal was estimated and expressed as cells per gland. In the colon, percentage of immunoreactive cells was determined in each crypt by selecting 10 glands using WinROOF image analysis and measurement software.
Statistical analysis
Values for real time RT-PCR and immunohistochemical cellular distribution in the kidney and liver were analyzed for homogeneity of variance using Bartlett's test. When the variance was homogenous among the groups, a one-way analysis of variance (ANOVA) was carried out. If significant differences were found, the mean value for each treatment group was compared to that of the controls using Dunnett's test. If a significant difference was found in variance using Bartlett's test, Steel's test was performed. Results from kidneys of treated animals were compared with either untreated controls or PNBA-or APAP-treated controls in Experiment 1. Results from livers of treated animals were compared with either untreated controls or APAP-or ANIT-treated controls in Experiment 2.
Distribution of immunoreactive cells in the thyroid, urinary bladder, forestomach, glandular stomach, and colon between groups were compared using Tukey's multiple comparison test if the variance using Bartlett's test was homogenous among the groups and if significant differences were found using a one-way ANOVA. If variances using Bartlett's test differed significantly, groups were compared using the Steel-Dwass multiple comparison test.
Number of cells showing co-expression in double immunohistochemistry was compared using Student's t-test when variance was proven to be homogenous between the groups, using a test for equal variance. If a significant difference in variance was observed, Welch's t-test was performed.
RESULTS
Histopathological changes in Experiments 1 and 2 Experiment 1
Histopathological renal changes were described previously (Taniai et al., 2012) . In brief, treatment with Fe-NTA resulted in degeneration and necrosis of the proximal tubules in the cortex and OSOM, accompanied with focal tubular regeneration showing scattered epithelial karyomegaly, as reported by others (Li et al., 1987) . Both OTA and MON treatment resulted in proximal tubular cell karyomegaly in the area limited to the OSOM by OTA and predominantly within the cortex by MON. These results are in agreement with previous reports (NTP, 1988; NTP, 1989; Adler et al., 2009) . PNBA treatment resulted in mild karyomegaly and scattered tubular regeneration in the cortical proximal tubules, as previously reported (NTP, 1994) . APAP treatment resulted in focal regeneration in the cortical proximal tubules. TRCP treatment resulted in scattered proximal tubular regeneration in the cortex and OSOM, and KBrO 3 treatment induced proximal tubular hyaline droplet accumulation and necrosis in the cortex, accompanied with scattered focal tubular regeneration. Proliferative lesions, such as atypical tubular hyperplasias, were not detected with any compounds.
Experiment 2
Treatment with TAA resulted in diffuse liver cell cytomegaly often associated with anisokaryosis, aberrant mitosis, and apoptosis, similar to previous finding (Clawson et al., 1992) . Bile duct proliferation and oval cell proliferation in the periportal area were evident and accompanied by mild interstitial fibrosis. Treatment with FB resulted in centrilobular liver cell hypertrophy, similar to previous findings (Shoda et al., 1999) . Periportal liver cells showed cytomegaly associated with anisokaryosis and scattered mitoses. PBO treatment induced diffuse liver cell hypertrophy associated with cytoplasmic ground glass appearance and moderate nuclear enlargement similar to the previous report (Muguruma et al., 2007) . Treatment with MEG resulted in diffuse distribution of cytomegalic liver cells associated with anisokaryosis, as previously reported (NTP, 2000) . Centrilobular liver cell necrosis was also scattered. Treatment with APAP resulted in increased cytoplasmic eosinophilia and ground glass appearance of liver cells (NTP, 1993) . Treatment with ANIT resulted in periportal bile duct proliferation and scattered focal liver cell necrosis and microgranulomas (Rees et al., 1962) . Proliferative lesions, such as altered liver cell foci, were not detected with any compounds.
Treatment with SDM resulted in scant colloidal fluid and follicular epithelial cell proliferation in the thyroid, leading to formation of small follicles consisting of large cuboidal cells, similar to previous findings (Imai et al., 2004) . Treatment with PEITC resulted in scattered foci of simple hyperplasia or papillary and nodular hyperplasia of the epithelia in the urinary bladder, similar to previous findings (Akagi et al., 2003) . Treatment with BHA resulted in hyperkeratosis/parakeratosis and hyperplasia of stratified epithelia in the forestomach (Hirose et al., 1987) . Treatment with catechol resulted in pyloric gland hyperplasia of the glandular stomach, similar to previous findings . Treatment with CDCA or PhIP did not induce any specific changes in the colon. Caprolactam as a non-carcinogenic control did not induce any changes in the epithelia of thyroid gland follicles, urinary bladder, forestomach, glandular stomach, or colon. Proliferative lesions and nuclear enlargement suggestive of karyomegaly/cytomegaly were not detected with any compounds.
Microarray and real-time RT-PCR analyses in Experiment 1
A total of 263 genes in the OSOM of rats administered Fe-NTA or OTA were up-regulated by ≥ 2-fold compared with untreated controls and by ≥ 1-fold compared with PNBA-treated controls. A total of 362 genes in the OSOM of rats administered Fe-NTA or OTA were downregulated by ≥ 2-fold compared with untreated controls and by ≥ 1-fold compared with PNBA-treated controls. By means of gene selection in terms of cell cycle-related function involving cell proliferation and apoptosis, we found 16 up-regulated genes related to cell proliferation (1 gene), apoptosis (5 genes), cell-cycle regulation associated with G 2 /M transition (5 genes), proteasome proteolysis (2 gene), p53 signaling pathway (2 genes), or cell growth (1 gene) ( Table 2) . Lists of all genes that met expression selection criteria are shown in Supplementary  Tables 1-6. Among 10 genes selected from those listed in Table 2 for confirmation of gene expression changes by real-time RT-PCR analysis, Mcm3, Casp12, Bbc3, Ubd, Cdkn1a, and Plk2 were significantly up-regulated following both Fe-NTA and OTA treatment as compared with untreat-ed controls (Fig. 2) . LOC687696 and Rprm were significantly up-regulated following Fe-NTA treatment only as compared with untreated controls. Gtse1 and LOC298795 were significantly up-regulated following OTA treatment only as compared with untreated controls. Mcm3, Bbc3, Ubd, and Cdkn1a were significantly up-regulated following both Fe-NTA and OTA treatment as compared with PNBA-treated controls. Casp12 was significantly up-regulated with Fe-NTA treatment only and Plk2 was significantly up-regulated with OTA treatment only as compared with PNBA-treated controls.
Distribution of Mcm3 + , Ubd + and TUNEL + cells in Experiment 1
Mcm3, a molecule involved in DNA replication and suggested to be a proliferation marker similar to Ki-67 (Lee et al., 2010) , was immunolocalized in the nuclei of proximal tubular epithelial cells (Fig. 3A) . All renal carcinogens tested, irrespective of karyomegaly-inducing potential, induced a significant increase in Mcm3 + cells in both the OSOM and the cortex + OSOM as compared with either untreated or APAP-treated controls. PNBA induced a significant increase in Mcm3 + cells in the cortex + OSOM as compared with untreated controls. Fe-NTA and OTA induced a significant increase in Mcm3 + cells in both the OSOM and cortex + OSOM as compared with PNBA-treated controls.
Ubd, also known as Fat10, functions as a ubiquitin-like proteinaceous tag when attached to a substrate protein, targeting the protein to the 26S proteasome for degradation (Herrmann et al., 2007) . Ubd was immunolocalized in the cytoplasm of proximal tubular epithelial cells ( Fig. 3B ). All renal carcinogens tested, irrespective of karyomegaly-inducing potential, induced a significant increase in Ubd + cells in both the OSOM and cortex + OSOM as compared with untreated controls. PNBA induced a significant increase in Ubd + cells in the cortex + OSOM as compared with untreated controls. OTA induced a significant increase in Ubd + cells in the OSOM and MON induced a significant increase in the cortex + OSOM as compared with PNBA-treated controls. OTA, MON, and TRCP each induced a significant increase in Ubd + cells in the OSOM as compared with APAP-treated controls. All renal carcinogens induced a significant increase in Ubd + cells in the cortex + OSOM as compared with APAP-treated controls. All renal carcinogens tested induced a significant increase in TUNEL + cells in both the OSOM and the cortex + OSOM as compared with untreated, PNBA-, or APAP-treated controls (Fig. 3C) . PNBA also induced a significant increase in TUNEL + cells in both the OSOM and the cortex + OSOM as compared with APAP-treated controls.
Distribution of Ki-67 + , Mcm3 + , Topo IIα + , Ubd + , and TUNEL + Cells in Experiment 2
TAA and MEG induced a significant increase in Ki-67 + cells in the liver as compared with untreated or non-carcinogen-treated controls (APAP and ANIT) (Fig. 4A) . FB and ANIT also induced a significant increase in Ki-67 + cells as compared with untreated controls, but with a lower magnitude of response than TAA or MEG. PBO did not cause an increase in Ki-67 + cells.
TAA, FB, and MEG induced a significant increase in Mcm3 + cells in the liver as compared with non-carcinogen treatments (APAP and ANIT), but not compared with untreated controls (Fig. 4B) . PBO did not cause an increase in Mcm3 + cells.
TAA, FB, and MEG induced a significant increase in Topo IIα + cells in the liver as compared with untreated or APAP-treated controls (Fig. 4C ). TAA and MEG also significantly increased Topo IIα + cells as compared with ANIT-treated controls. PBO did not cause in increase in Topo IIα + cells.
TAA, FB, and MEG induced a significant increase in Ubd + cells in the liver as compared with untreated or APAP-treated controls (Fig. 4D) . TAA and MEG also induced a significant increase in Ubd + cells as compared with ANIT-treated controls. PBO did not cause in increase in Ubd + cells.
TAA and MEG induced a significant increase in TUNEL + cells in the liver as compared with untreated or non-carcinogen-treated (APAP or ANIT) controls (Fig. 4E) . FB induced a significant increase in TUNEL + cells as compared with APAP-treatment. PBO did not cause a significant increase in TUNEL + cells.
SDM induced significant increases in Ki-67 + , Mcm3 + , Topo IIα + , and Ubd + cells in the thyroid as compared with untreated or caprolactam-treated controls (Figs. 5A-E). SDM did not induce a significant increase in TUNEL + cells, while the value was higher than untreated and caprolactam-treated controls. PEITC induced significant increases in Ki-67 + , Mcm3 + , Topo IIα + , Ubd + , and TUNEL + cells in the urinary bladder as compared with untreated or caprolactam-treated controls (Figs. 5A-E) . Caprolactam also significantly increased Ki-67 + cells as compared with untreated controls.
BHA induced significant increases in the length of distribution of Ki-67 + , Mcm3 + , and Topo IIα + cells, and the number of TUNEL + cells in the forestomach as compared with untreated or caprolactam-treated controls (Figs. 6A-E) . BHA induced a significant increase in Ubd + cells as compared with untreated controls only.
Catechol induced significant increases in Mcm3 + , Topo IIα + , and TUNEL + cells in the glandular stomach as compared with untreated or caprolactam-treated controls (Figs. 6A-E) . Catechol induced significant increases in Ki-67 + and Ubd + cells as compared with untreated controls only. CDCA and PhIP did not induce significant increases in any marker in the colon as compared with untreated or caprolactam-treated controls (Figs. 7A-E) .
Real-time RT-PCR analysis of Tp53 and apoptosis-related genes in Experiment 1
Fe-NTA and OTA induced a significant increase in proapoptotic Bax transcript levels in the OSOM as compared with untreated or PNBA-treated controls (Fig. 8) . Fe-NTA and OTA induced a slight increase in Tp53 transcript level as compared with PNBA-treated controls. Only OTA induced a significant increase in Tp53 transcript levels compared with untreated controls. OTA induced slight, but significant increases in Bcl2 and Bcl2l1 transcript levels as compared with untreated controls (Bcl2l1) or PNBA-treated controls (Bcl2 and Bcl2l1).
Double immunohistochemistry of Ubd with Topo IIα and p-Histone H3
OTA unchanged the number of p-Histone H3 + cells within the population of Ubd + cells as compared with untreated controls in the OSOM (Fig. 9A) . TAA significantly decreased the number of p-Histone H3 + cells within the population of Ubd + cells as compared with untreated controls in the liver. Both carcinogens significantly increased the number of Ubd + cells within the population of Topo IIα + cells as compared with untreated controls (Fig. 9B) . On the other hand, OTA unchanged the number of Ubd + cells within the population of p-Histone H3 + cells as compared with untreated controls (Fig. 9C) . 
DISCUSSION
Our previous study demonstrated that renal carcinogens, irrespective of karyomegaly-inducing potential, increased cell proliferation activity measured with the number of Ki-67 + cells and immunoreactivity for Topo IIα in the OSOM and cortex + OSOM following 28 days of treatment (Supplementary Fig. 1 ; Taniai et al., 2012) . In the present study, we investigated immunohistochemically another cell proliferation marker (Mcm3) and a molecule related to deregulation of G 2 /M phase (Ubd: Lim et al., 2006) , as well as TUNEL + apoptotic cells in the kidney tissues. These markers were selected based on the previous study's results and the present microarray data in the OSOM of rats exposed to karyomegalyinducing carcinogens for 28 days. We found that all renal carcinogens, irrespective of the karyomegaly-inducing potential, increased distribution of Mcm3 + and Ubd + cells and TUNEL + apoptotic cells in the OSOM and cortex + OSOM. We also found many carcinogens specifically targeting the liver, thyroid, urinary bladder, forestomach, and glandular stomach, also induced increases in Ki-67 + , Mcm3 + , Topo IIα + and Ubd + cells, and TUNEL + apoptotic cells in their respective target organs. However, some carcinogens lacking induction of cell proliferation as estimated by the number of Ki-67 + and Mcm3 + cells in the target organ, such as PBO in the liver and CDCA and PhIP in the colon, did not increase Topo IIα + and Ubd + cells, and apoptosis.
Entry into mitosis (i.e., the G 2 /M transition) is regulated by several checkpoint control pathways which cease to delay or stop further cell cycle progression once the cell becomes committed to divide (reviewed in Rieder, 2011) . When the mitotic checkpoint is disrupted in normal cells, they are delayed in mitosis for hours. However, many types of neoplastic cells die after a prolonged mitotic arrest by apoptosis under this condition. In the present study, we observed concomitant increases in apoptosis and cell proliferation similar to cells deregulating G 2 /M phase in the renal tubules from rats after treatment with renal carcinogens. This result suggests that renal cells, despite not being neoplastic, facilitate cell proliferation accompanying aberrant regulation of G 2 /M transition leading to apoptosis.
With regard to the up-regulation of pro-apoptotic genes, Casp12, Bik, and Bbc3 (also known as Puma) in the OSOM, as demonstrated by microarray data, suggests that OTA and Fe-NTA facilitate apoptosis. By realtime RT-PCR analysis, we also observed that OTA treatment increased transcript levels of Bax, Tp53, Bcl2, and Bcl2l1 (also known as BclxL), while Fe-NTA only slightly increased transcript levels of Bax and Tp53. Cumulative data indicate that anti-apoptotic Bcl-2 and Bcl2l1 mediate both survival and quiescence of cells leading to G 0 arrest in response to DNA damage, while pro-apoptotic Bax promotes both cell death and cell cycle upon activation of a cell death signal (Zinkel et al., 2006) . These results suggest that some renal carcinogens facilitate apoptosis and cell cycling concurrently with an increase of arrested cell populations. Increased apoptosis reflecting aberrant cell cycle regulation may be the common feature of renal carcinogens that show high proliferative activity after a 28-day treatment.
It has been proposed that a non-genotoxic mode of action to induce hepatocellular apoptosis with subsequent regeneration (proliferation) is responsible for the hepato- carcinogenicity of fumonisin B 1 mycotoxin (Dragan et al., 2001) . In the present study, we found increased proliferation and apoptosis of liver cells as well as increased cellular populations immunoreactive with Topo IIα and Ubd following treatment with either TAA, FB, or MEG. However, we did not observe increased proliferation or apoptosis of liver cells following PBO treatment, suggesting that hepatocarcinogens concurrently induced apoptosis and activation of cell proliferation in the liver. Tumor-promoting potential of hepatocarcinogens in a rat two-stage hepatocarcinogenesis model correlates well with their hepatocarcinogenic potential (Shirai, 1997) . In our previous study, we found that TAA and FB had higher tumor promoting potential than PBO (Ichimura et al., 2010) . MEG is a strong hepatocarcinogen that has shown induction of hepatocellular adenomas and carcinomas in rats by repeated oral administration at 300 mg/kg/day even at the one-year interim sacrifice (NTP, 2000) . This dose is less than one-third of the dose level in the present study. Therefore, the lack of proliferation activity with PBO in the present study may be a reflection of its weaker carcinogenic potential as compared with TAA, FB, and MEG. Other organ-specific carcinogens examined in the present study induced responses similar to those observed in the kidney, including SDM for the thyroid, PEITC for the urinary bladder, BHA for the forestomach, and catechol for the glandular stomach. The hypothyroidismrelated mechanism of SDM involves a decrease in the serum levels of thyroid hormone causing suppression of negative feedback through the pituitary and an increase in serum thyroid-stimulating hormone (TSH) in rats (Imai et al., 2004) . TSH then stimulates thyroid functions, including growth and proliferation of follicular cells as a link to carcinogenesis (Hard, 1998) . PEITC activates cell proliferation of the urothelium early after administration due to cytotoxic oxidative DNA damage (Akagi et al., 2003) . BHA and catechol induce cell proliferation in response to gastric epithelial erosion/ulceration . These observations suggest that there are carcinogens, irrespective of target organs, with a potential for induction of proliferation of target cells accompanied with cell cycle arrest and apoptosis in 28-day treatment scheme.
On the other hand, CDCA and PhIP as colonic carcinogens did not alter cellular distribution of the selected markers in the present study. CDCA given in diet for 2 weeks can dose-dependently promote proliferation of colonic mucosal cells after initiation with azoxymethane (AOM) (Sutherland and Bird, 1994) . However, CDCA without AOM-initiation only increased cell proliferation at low doses. In that study, higher doses of CDCA ( ≥ 1,000 ppm), the dose level used in the present study, did not increase colonic mucosal cell proliferation. Dietary administration of 400 ppm PhIP slightly increased colonic mucosal cell proliferation after an 8-week treatment, but proliferation was not increased after a 4-week treatment (Ochiai et al., 1996) . Therefore, it is possible that these colon carcinogens would not induce cell proliferation in a 28-day treatment scheme. While the reason for the lack of proliferation activity may differ between organ-specific carcinogens, detection of cell proliferation activity at different time points, combined with the cellular markers identified in this study, may effectively predict carcinogenic potential of compounds. Although the reason was not clear, large differences in the positive cell ratio of Mcm3 , and Ubd in the untreated and caprolactam-treated controls probably related to the difference in the experimental conditions were observed between the CDCA and PhIP studies.
It was previously reported that the peaked expression level of Topo IIα is observed at G 2 /M phase showing highest activation (Woessner et al., 1991; Adachi et al., 1997; Lee et al., 2004) . In the present study, we found increased co-expression of Ubd with Topo IIα in carcinogenic target cells with OTA or TAA, while co-expression of Ubd with p-Histone H3 did not change or mildly decreased with these carcinogens. Considering that p-Histone H3 is a specific marker of M phase (Beekman et al., 2006) , increased co-expression of Ubd with Topo IIα by these carcinogens may reflect aberrantly increased Ubd + population at G 2 phase. It is reported that excess Ubd leads to chromosomal instability through reduction of kinetochore localization of spindle checkpoint proteins such as Mad2 (Lim et al., 2006; Herrmann et al., 2007) . Therefore, carcinogens that evoke cell proliferation may increase cellular population undergoing M phase disruption that eventually leads to chromosomal instability linked to carcinogenesis.
Overexpression of Topo IIα indicates a high level of proliferation in neoplastic cells (Pentheroudakis et al., 2010) . We have previously demonstrated that an increase in Topo IIα + cells indicates cell proliferation following treatment with renal carcinogens (Taniai et al., 2012) . Our results suggest that fluctuations in Topo IIα + cells mimic the cell proliferation activity because of its induction during the majority of active cell cycle phases (Bower et al., 2010) , and among them, co-expression of Ubd reflects aberrant activation of Ubd at G 2 phase.
In conclusion, carcinogens that evoke cell proliferation in a 28-day treatment scheme can also induce aberrant expression of Topo IIα and Ubd and apoptosis, irrespective of target organs examined here. Carcinogens lacking proliferative activity did not have these effects. Further-more, increased Ubd + population was observed in carcinogenic target cells at G 2 phase as examined with OTA and TAA. These results suggest that aberrant expression of Ubd at G 2 phase and increased apoptosis reflecting aberrant cell cycle regulation may be the common feature of carcinogens that show high proliferative activity after a 28-day treatment in many target organs.
